Product Description
IC-200 is a gene therapy program designed by Iveric Bio. (Sourced from: https://investors.ivericbio.com/news-releases/news-release-details/iveric-bio-reports-first-quarter-2021-operational-highlights-and)
Mechanisms of Action: Gene Therapy,USH2A
Novel Mechanism: Yes
Modality: Gene Therapy
Route of Administration: Intraocular
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: IVERIC bio
Company Location: NEW YORK NY 10001
Company CEO: Glenn P. Sblendorio
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: